Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 11, 2011 - Issue 3
Submit an article Journal homepage
250
Views
24
CrossRef citations to date
0
Altmetric
Drug Evaluations

ETC-216 for coronary artery disease

Stephen J Nicholls Heart & Vascular Institute, Cleveland Clinic, Department of Cardiovascular Medicine, Mail Code JJ-65, 9500 Euclid Avenue, Cleveland, OH 44195, USA +1 216 444 2678; +1 216 445 5497; [email protected]; Cleveland Clinic, Department of Cell Biology, Cleveland, OH, USA; Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, OH, USA
,
Kiyoko Uno Heart & Vascular Institute, Cleveland Clinic, Department of Cardiovascular Medicine, Mail Code JJ-65, 9500 Euclid Avenue, Cleveland, OH 44195, USA +1 216 444 2678; +1 216 445 5497; [email protected]
,
Yu Kataoka Heart & Vascular Institute, Cleveland Clinic, Department of Cardiovascular Medicine, Mail Code JJ-65, 9500 Euclid Avenue, Cleveland, OH 44195, USA +1 216 444 2678; +1 216 445 5497; [email protected]
&
Steven E Nissen Heart & Vascular Institute, Cleveland Clinic, Department of Cardiovascular Medicine, Mail Code JJ-65, 9500 Euclid Avenue, Cleveland, OH 44195, USA +1 216 444 2678; +1 216 445 5497; [email protected]
Pages 387-394 | Published online: 28 Jan 2011

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Stephen J Nicholls. (2014) Examining controversies and new frontiers in lipid management. Clinical Lipidology 9:5, pages 587-595.
Read now

Articles from other publishers (23)

Amin Javadifar, Sanaz Ahmadi Ghezeldasht, Hossein Rahimi, Narges Valizadeh, Zahra Rezaei Borojerdi, Zohreh Vahidi & Seyed Abdolrahim Rezaee. (2022) Possible deterioration of Apolipoproteins expression by HTLV-1 infection in favor of infected leukemic cells in adult T-cell leukemia/lymphoma (ATLL). Gene Reports 26, pages 101531.
Crossref
Evangelia Zvintzou, Dimitra Sotiria Karampela, Aggeliki Vakka, Eva Xepapadaki, Eleni A. Karavia, Aikaterini Hatziri, Panagiota C. Giannopoulou & Kyriakos E. Kypreos. (2021) High density lipoprotein in atherosclerosis and coronary heart disease: Where do we stand today?. Vascular Pharmacology 141, pages 106928.
Crossref
Aditya Gupta, Reena Sharma, Kaushik Kuche & Sanyog Jain. (2021) Exploring the therapeutic potential of the bioinspired reconstituted high density lipoprotein nanostructures. International Journal of Pharmaceutics 596, pages 120272.
Crossref
Jiansheng Huang, Dongdong Wang, Li-Hao Huang & Hui Huang. (2020) Roles of Reconstituted High-Density Lipoprotein Nanoparticles in Cardiovascular Disease: A New Paradigm for Drug Discovery. International Journal of Molecular Sciences 21:3, pages 739.
Crossref
Joannes A. A. Reijers, Karen E. Malone, Jeffrey J. Bajramovic, Richard Verbeek, Jacobus Burggraaf & Matthijs Moerland. (2019) Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals. British Journal of Clinical Pharmacology 85:7, pages 1418-1426.
Crossref
Laura Z. VanagsNathan K.P. WongStephen J. NichollsChristina A. Bursill. (2018) High-Density Lipoproteins and Apolipoprotein A-I Improve Stent Biocompatibility. Arteriosclerosis, Thrombosis, and Vascular Biology 38:8, pages 1691-1701.
Crossref
Kohei Takata, Belinda A. Di Bartolo & Stephen J. Nicholls. (2018) High-Density Lipoprotein Infusions. Cardiology Clinics 36:2, pages 311-315.
Crossref
Joannes A. A. Reijers, D. G. Kallend, K. E. Malone, J. W. Jukema, P. L. J. Wijngaard, J. Burggraaf & M. Moerland. (2017) MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216. Cardiovascular Drugs and Therapy 31:4, pages 381-389.
Crossref
Godfrey S. Getz & Catherine A. Reardon. (2017) Genetic control of apoprotein A-I and atheroprotection. Current Opinion in Lipidology, pages 1.
Crossref
Hong Y. Choi, Anouar Hafiane, Adel Schwertani & Jacques Genest. (2017) High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management. Canadian Journal of Cardiology 33:3, pages 325-333.
Crossref
Yunlong Wang, Yanhui Wang, Shaoyou Jia, Qingzhe Dong, Yuanbin Chen, Shulai Lu & Lin Hou. (2017) Effect of lipid-bound apolipoprotein A-I cysteine mutant on ATF3 in RAW264.7 cells. Bioscience Reports 37:1.
Crossref
C. Shad Thaxton, Jonathan S. Rink, Pratap C. Naha & David P. Cormode. (2016) Lipoproteins and lipoprotein mimetics for imaging and drug delivery. Advanced Drug Delivery Reviews 106, pages 116-131.
Crossref
Emily E. Morin, Ling Guo, Anna Schwendeman & Xiang-An Li. (2015) HDL in sepsis – risk factor and therapeutic approach. Frontiers in Pharmacology 6.
Crossref
Anouar Hafiane, Samantha Kellett & Jacques Genest. (2014) Treatment options for low high-density lipoproteins. Current Opinion in Endocrinology, Diabetes & Obesity 21:2, pages 134-139.
Crossref
SEONG-MIN KIM, GA-YOUNG PARK, INHO CHOI & KYUNG-HYUN CHO. (2013) Bovine apolipoprotein (apo)A-I displays more enhanced antioxidant and anti-atherosclerotic activity in lipid-free and lipid-bound states than human and porcine apoA-I. International Journal of Molecular Medicine 32:4, pages 843-850.
Crossref
Jongwoo KimSeon Yeong Lee. (2013) Obesity and High-density lipoprotein Cholesterol (HDL-C) : The Recent Related Research Trend Including New Generation Drugs for HDL-C. The Korean Journal of Obesity 22:2, pages 67.
Crossref
Ayako Kamei, Paul S. Hauser, Jennifer A. Beckstead, Paul M.M. Weers & Robert O. Ryan. (2012) Expressed protein ligation-mediated template protein extension. Protein Expression and Purification 83:2, pages 113-116.
Crossref
Andrea J. Luthi, Heng Zhang, Dongwoo Kim, David A. Giljohann, Chad A. Mirkin & C. Shad Thaxton. (2011) Tailoring of Biomimetic High-Density Lipoprotein Nanostructures Changes Cholesterol Binding and Efflux. ACS Nano 6:1, pages 276-285.
Crossref
Anatol Kontush & M. John Chapman. 2011. High‐Density Lipoproteins. High‐Density Lipoproteins 423 523 .
Wentao Zhao, Fen Du, Michelle Zhang, Shengfang Sun, Hong Yu & Daping Fan. (2011) A new recombinant human apolipoprotein E mimetic peptide with high-density lipoprotein binding and function enhancing activity. Experimental Biology and Medicine 236:12, pages 1468-1476.
Crossref
Stephen J. Nicholls. (2011) Apo A-I Modulating Therapies. Current Cardiology Reports 13:6, pages 537-543.
Crossref
Santiago Redondo, Jos? Mart?nez-Gonz?lez, Concha Urraca & Teresa Tejerina. (2011) Emerging therapeutic strategies to enhance HDL function. Lipids in Health and Disease 10:1, pages 175.
Crossref
Kewal K. JainKewal K. Jain. 2011. Applications of Biotechnology in Cardiovascular Therapeutics. Applications of Biotechnology in Cardiovascular Therapeutics 1 27 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.